Trial Profile
A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination With Nivolumab in Subjects With Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC), and Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 15 Nov 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Tucidinostat (Primary)
- Indications Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions
- Sponsors HUYA Bioscience International
- 08 Nov 2023 Status changed from active, no longer recruiting to completed.
- 27 Feb 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Sep 2023.
- 12 Oct 2022 Planned primary completion date changed from 1 Aug 2022 to 1 Dec 2022.